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Abstract 
Many models of disease progression in Alzheimer’s disease (AD) have been proposed to help guide 
experimental design and aid the interpretation of results. Models focussing on the genetic evidence 
include the amyloid cascade (ACH) and presenilin (PSH) hypotheses and the amyloid precursor 
protein (APP) matrix approach (AMA), of which the ACH has held a dominant position for over two 
decades. However, the ACH has never been fully accepted and has not yet delivered on its 
therapeutic promise.  We review the ACH, PSH and AMA in relation to levels of APP proteolytic 
fragments reported from AD-associated mutations in APP. Different APP mutations have diverse 
effects on the levels of APP proteolytic fragments. This evidence is consistent with at least three 
disease pathways that can differ between familial and sporadic AD and two pathways associated 
with cerebral amyloid angiopathy. We cannot fully evaluate the ACH, PSH and AMA in relation to the 
effects of mutations in APP as the APP proteolytic system has not been investigated systematically. 
The confounding effects of sequence homology, complexity of competing cleavages and antibody 
cross reactivities all illustrate limitations in our understanding of the roles these fragments and the 
APP proteolytic system as a whole in normal aging and disease play. Current experimental design 
should be refined to generate clearer evidence, addressing both aging and complex disorders with 
standardised reporting formats. A more flexible theoretical framework capable of accommodating 
the complexity of the APP proteolytic system is required to integrate available evidence. 
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Introduction 
 
Alzheimer’s disease (AD) is a clinicopathologically defined condition associated with aging and 
genetic causative or risk factors that leads to increasing cognitive impairment, difficulties in everyday 
living and neurodegeneration. There is no single accepted cause. In early-onset inherited forms of 
AD (FAD), accounting for <1% of dementia cases in populations [1], the presence of fully penetrant 
mutation in the amyloid precursor protein (APP), presenilin (PS) 1 (PSEN1) or more rarely PS 2 
(PSEN2) confirms a diagnosis of AD. In late-onset sporadic AD (SAD), accounting for the majority of 
dementia syndrome, a clinical diagnosis can only be “probable” AD [2, 3] and is confirmed 
neuropathologically after death by deposits of amyloid beta protein (Aβ) and the presence of 
aggregated microtubule associated protein tau in neurofibrillary tangles (NFT) and neuritic plaques 
(NP) [4, 5]. Increasing use is being made of clinical imaging and standardised diagnostic criteria have 
been proposed [6] however, imaging and other biomarkers do not always correlate [7, 8]. AD-
associated pathology may be present in those without cognitive impairment  [9], does not correlate 
well with clinical dementia, and is associated additionally with ageing [10], raising questions around 
what the neuropathology represents. Dementia in the older population is rarely “pure” AD, and 
presents neuropathologically with mixed vascular and degenerative features [11, 12].  Thus, while 
the co-segregation of pathogenic and fully penetrant mutations within the same family permits 
diagnosis of monogenic FAD with a high degree of certainty, there is currently no unified clinical, 
neuropathological or molecular definition of SAD [13, 14]. 
 
Various experimental approaches have contributed to the body of evidence relating to AD. Clinical 
[2, 3, 15] and neuropathological features [4, 5] have been described. Blood and cerebrospinal fluid 
based biomarkers [16, 17], and MRI with markers such as Pittsburgh compound B [18] are being 
developed with the aim of following disease progression in humans. However, no marker reliably 
associates with clinical dementia [16, 18] in diagnosis or disease progression.  
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Various hypotheses have been proposed to guide investigations into disease pathways associated 
with AD, focussing on areas known to be perturbed in AD including the immune system [19-22], 
mitochondria and oxidative stress [23, 24], metabolism and diabetes [25-28], cholesterol regulation 
[29, 30], cell cycle [31, 32], neurotransmitters including acetylcholine in synaptic plasticity [33-37] 
and the role of tau deposition and tau oligomers  [38-42]. However, none of these relate directly to 
interpreting the genetic evidence regarding the role of APP mutations in FAD. Hypotheses relating to 
the genetic evidence include the amyloid cascade hypothesis (ACH) [43-45], the presenilin 
hypothesis (PSH) [46] and the APP matrix approach (AMA) [47, 48] and of these, the ACH has 
maintained a dominant position guiding research for over two decades.  
 
The ACH has not been universally accepted and periodic discussions have raised questions relating 
to the assertion that Aβ is causal in all forms of AD [14, 49-52] and instead highlight the complexity 
of the APP proteolytic system. Supporters of the ACH have referred to genetic evidence, where 
mutations associated with FAD lead to change in the expression of the various Aβ peptides, and 
Occam’s razor, where clinical and neuropathological presentations of those with AD of both familial 
and sporadic forms share common features and so should be approached therapeutically as similar 
entities. Those that don’t accept the ACH cite human studies where evidence is highly heterogenic 
[1, 12, 53, 54] and suggest that multiple pathways are possible [48]. The argument has two main 
perspectives, either Aβ is causal in AD and represents a unifying pathway to disease or complexity 
leads to multiple disease pathways.  
 
Given that recent clinical trials guided by the ACH have not been as successful as hoped [55], it is 
important at this time to examine these hypotheses in greater detail with respect to accumulating 
evidence to see where failures in the translation of pre-clinical research to the human population 
might occur. Using mutations in APP as an illustrative example, we ask whether the research 
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community is well guided by the current hypotheses or whether a change in approach might bring 
new understanding.  
 
The amyloid cascade hypothesis 
 
The ACH interprets the genetic evidence from FAD to suggest that fully penetrant mutations in APP 
and PSENs lead to changes in the levels of neurotoxic Aβ that initiate AD pathways [44, 45]. The 
original hypothesis, (Figure 1a), proposed that AD was caused by increased levels of Aβ however, 
this has been updated to include increased ratio of Aβ(1-42)/Aβ(1-40) [44, 45] or oligomers [56, 57]. 
All other features of AD, such as tau aggregation, inflammation, reduced metabolism, perturbed 
neural networks and cognitive impairments are proposed to follow on from causal events associated 
with increased Aβ [44, 45, 57]. The ACH assumes that all FAD mutations share molecular pathways 
associated with increases in neurotoxic forms of Aβ and in SAD, increased levels of Aβ, perhaps due 
to impaired degradation and clearance, contribute to disease [58, 59], therefore all FAD will respond 
to the therapeutic removal of Aβ. The ACH proposes that since SAD and FAD share common clinical 
and neuropathological features, then by Occam’s razor, the simplest explanation suggests that FAD 
and SAD also share these disease mechanisms and therapeutic strategies developed for FAD should 
be applicable in SAD.  
 
The presenilin hypothesis 
 
~95% of FAD is caused by mutations in PSEN1. The PSH [46, 60], (Figure 1b), interprets the genetic 
data from PSENs mutations as showing loss of PS function, with several mutations showing almost 
complete abolition of γ-secretase activity with loss of physiologically relevant Aβ [60-63]. This 
contrasts with the over-production of Aβ or Aβ42 required by the ACH. However, some suggest that 
PSENs associated pathways may involve gain of function effects that are compatible with the ACH 
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such as increased Aβ42/43 [64-67]. Complex patterns of both gain and loss of PS functions that vary 
with each mutation [68] may better describe the contributions of PSENs mutations to variations 
seen  in clinical features such as age of onset and seizures  [69] and neuropathology [70].  
 
The results from the randomised controlled trial of the γ-secretase inhibitor Semagacestat showing a 
worsening of dementia with increased risk of skin cancer [71] coupled with recent evidence of no 
clear associations between age of onset and Aβ levels or Aβ40/Aβ42 [62] support the PSH and 
suggest that enhancing γ-secretase could be a valuable therapeutic approach. Recent 
neuropathological evidence of increased size and number of cored amyloid plaques coupled with 
more severe cerebral amyloid angiopathy (CAA) and plaque distribution around vessels in those with 
PSEN1 mutations after codon 200 compared to those with mutations before codon 200 suggest that 
PSEN1 mutations may be associated with at least 2 disease pathways [72]. Whether these pathways 
relate to the dual carboxypeptide pathways associated with the production of Aβ [67] remains to be 
investigated.  
 
Differences in levels of Aβ40 and Aβ42 [73] and differences in the APP β carboxy terminal fragment 
[74] between PSENs associated FAD and SAD, raise questions relating to the general applicability of 
the PSH.  While studies have shown a rare coding variability in PSEN1 may influence the 
susceptibility for apparently sporadic late-onset AD [75, 76], increases in Aβ production may not 
explain the majority of SAD cases. The PSH suggests that APP mutations around the α-, β’- and β- 
cleavage sites may act via conformational change to alter γ-cleavages, however, it is equally possible 
that this hypothesis may not be relevant to all FAD deriving from mutations in APP around the α-, β’- 
and β- cleavage sites. As with the ACH, the PSH focuses on Aβ as the outcome of interest however it 
could be usefully updated to include considerations of all products from γ-cleavage since loss or gain 
of function may affect all products equally [77]. The PSH allows for multiple pathways depending on 
the exact nature of the change in γ-cleavage arising from the different PSENs mutations [78]. The 
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complex mix of gain and loss of function for different PSENs mutations suggests that one therapeutic 
approach may not be adequate. A detailed investigation of the relationships between specific PSENs 
mutations and Alzheimer disease pathways is beyond the scope of this review however, a similar 
approach examining the proteolytic fragments for each PSENs mutation could usefully clarify our 
understanding of the contributions of PSENs mutations to AD pathways. 
 
The amyloid precursor protein matrix approach 
 
The AMA considers the effects of genetic mutations against the background of dynamic complexity 
of the APP proteolytic system as a whole. Mutations in APP may alter the balance between the 
different functional areas of this complex system with consequences for a wide variety of cellular 
processes, (Figure 1c). The functional consequences arising from APP proteolysis can be understood 
in terms of a dynamic balance between full length APP and fragments from the α- and β’- and β- 
cleavages as reflected in the ratios of sAPPα/sAPPβ/sAPPβ’/full length APP in functional module A, 
coupled with functions arising from the synergetic interactions of the P3-type/β’-type/Aβ-type 
fragments arising from γ-cleavage in functional module B. There are additional functional effects 
arising from the carboxy terminal membrane fragments (CTFs) following α-, β’- and β- cleavages, the 
various AICDs following γ- ε- and ζ- cleavages, and caspase cleavage [79]. The levels of sAPPβ/sAPPα 
may not mirror the levels of the Aβ- type/P3-type peptides as Aβ1-14/15/16 fragments generated 
either from the C99 membrane fragment [80] or as a product of Aβ catabolism [81, 82] have been 
reported. Additional η-cleavage has recently been reported, increasing the complexity of this 
proteolytic system [83, 84]. The expression level of APP, increased in Down syndrome (DS) and 
people with APP duplications, has been shown to be rate limiting in the production of Aβ [82], 
suggesting that α-, β- and other cleavages compete.  
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According to the AMA, the APP/PS proteolytic system is in dynamic balance around a homeostatic 
point that allows proper neuronal function. Shifts to either α- or β- pathways may be regulated by 
wide ranging factors from cholesterol to inflammation and synaptic activity and the system is able to 
feed forward iteratively via the ever changing ratios of proteolytic fragments that affect the same 
cell systems involved in its regulation [47, 48, 85]. Each mutation has the potential to alter the 
balance between the cleavage products and change the behaviour of the fragments to varying 
degrees depending on changes to hydrophobicity, electrostatic charge and aggregation properties. 
This can involve different gains or losses of function for each of the fragments and full length APP for 
each mutation. In effect the APP proteolytic system allows partial contributions to disease from 
various cellular systems via the complex regulation of all cleavage products in APP proteolysis, 
including Aβ.  While genetic mutations in FAD potentially alter the balance in the APP proteolytic 
system, changes in the way that different feedback relationships from neuronal systems such as 
cholesterol homeostasis, immune signalling and synaptic plasticity also potentially alter this balance, 
leading to the possibility of multiple disease pathways.  
 
In order to evaluate the hypotheses with respect to the relationships between mutations in APP and 
FAD, we examined the consequences of the various APP mutations on the levels of the peptide 
fragments resulting from the APP proteolytic system in studies describing human mutations, 
presented in Table 1 and Supplementary Table 1. APP duplications and triosomy of chromosome 21 
found in DS have been included in Table 1 and Supplementary Table 1 for completeness however, 
given the limited space available, they are discussed only briefly. We considered the evidence from 
the different perspectives of the alternative hypotheses. 
 
Experimental design, missing data and standardisation 
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No study in Supplementary Table 1 systematically measured all the APP proteolytic fragments and 
the roles of different APP proteolytic fragments have not been extensively investigated yet. While 
the Aβ-type fragments are well represented, other fragments are not, illustrating that our 
understanding of this complex proteolytic system is incomplete. Specifically, levels of APP, the large 
N-terminal sAPPα and sAPPβ, the membrane bound C-terminal fragments (CTF), the P3-type 
peptides and the various APP intracellular domains (AICD) are not well reported. Evidence relating to 
the APP proteolytic system as a synergistic whole is absent from the literature. From the perspective 
of the AMA, which focuses on the dynamic balance between all fragments in relation to the cellular 
environment, the distribution of evidence in Supplementary Table 1 shows that a full understanding 
of this system is not possible - too much evidence is missing. Although complexity in APP physiology 
and biochemistry has always been given as an alternative perspective [47-49, 52, 85, 86], this has 
not been considered in experimental design to date. The confounding complexity in the APP 
proteolytic system is highlighted in a recent investigation of anti Aβ antibody cross reactivities [87]. 
Cross reactivities of commonly used antibodies may undermine current interpretations of 
immunoreactivity and this is especially relevant to neuropathological investigations where only one 
antibody per feature may be used [72]. The antibody BC05, recognising Aβ C-terminals ending at 
amino acid 42 or 43, also recognises P3-42/43. BA07, recognising Aβ C-terminal ending at amino acid 
40 also recognises P3-40, however very few experimental designs control for this cross reactivity and 
studies interpret immunoreactivities erroneously as representing Aβ. This confounding affects other 
antibodies raised against C-terminals [77]. Further cross reactivity may also derive from catabolic 
fragments of Aβ or Aβ’ from cleavage by BACE2 [87]. From the perspective of the ACH, this may not 
be so important as P3 is not suggested to play a significant role in disease, from the perspective of 
the AMA, this is a fundamental confound between two or more cleavage pathways and the 
neuropathological evidence especially should be urgently clarified. Given the potential confounding 
of evidence relating to Aβ by P3- type and smaller catabolic peptides, current experimental design 
cannot support interpretations of Aβ as causal nor eliminate considerations of complexity from 
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disease pathways, raising profound implications for AD research strategies. Experimental designs 
should be adjusted to explicitly measure and report all proteolytic fragments where sequence 
homology predicts confounding. Mass spectrometry may be preferable to western blotting in 
conjunction with a panel of capture antibodies to identify each peptide [88]. 
 
Few studies have focussed on P3 type peptides, despite evidence that P3 is known to aggregate [89-
92], has been associated with cotton wool type amyloid plaques [93, 94], is present in CAA [95], 
enhances the aggregation of Aβ1-40 [96],  may have a signalling role in apoptosis via caspase 
activation[97], form Ca2+ channels [98] and may be affected similarly to Aβ by changes to γ-cleavage 
[77]. P3 peptides are not thought to contribute to disease progression in the ACH and their roles in 
disease and healthy ageing have largely been ignored. The AMA predicts modulatory relationships 
between P3-type and Aβ-type fragments in their predicted interactions as small binding proteins, 
(Figure 1c, functional module B), however, current experimental design is inadequate for 
investigations from this perspective as the AMA requires that each APP proteolytic fragment must 
be measured in any investigation. Neither the ACH nor PSH consider all fragments from the APP 
proteolytic system. 
 
The use of cellular systems to investigate expression levels of Aβ is a useful approach to 
characterising these mutations and has been shown to reflect the amount deposited in the human 
brain [72]. In addition to different experimental procedures and the use of different cell models, 
(Supplementary Table 1), the reporting of the various expression levels of the proteolytic fragments 
is not standardised, making comparison between studies difficult beyond a qualitative measure of 
increase/decrease or no change. Some studies report concentrations as ng/ml-1 or Molar values [99-
104], values normalised to full length APP levels [105-110] or total Aβ levels [111-113], relative to 
cell number [114, 115] or relative to WT/control [116-121]. Standardised reporting and experimental 
protocols would be useful in comparisons between studies. Given the different experimental 
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approaches, the qualitative changes in Table 1 appear generalizable and robust. However, given that 
evidence relating to Aβ is potentially confounded due to cross-reactivity of antibodies [87] we 
cannot be certain that these data are not confounded by P3.  
 
Does evidence from FAD due to APP mutation describe one or many disease pathways? 
 
Although the evidence for some mutations is sparse, the mutations can be grouped according to 
change in expression levels of the various Aβ fragments, (Table 1 and Figure 2). Group 1 shows 
increases in total [Aβ], Aβ40, Aβ42 and the Aβ42/Aβ40 ratio and is associated with mutations 
around the α-secretase site, (Table 1, Figure 2). Mutations in group 1, leading to increased Aβ 
expression, are compatible with the ACH. Group 2, including the protective APP p.A673T mutation 
[101] and mutations specific to APP at codon 693, shows reduced total [Aβ], Aβ40, Aβ42 and the 
Aβ42/Aβ40 ratio, (Table 1, Figure 2). Group 3 has reduced total [Aβ] and Aβ40 combined with 
increased Aβ42 and the Aβ42/Aβ40 ratio and these mutations are associated with the γ- secretase 
site, (Table 1, Figure 2). This third group also compares well with PSENs mutations showing similar 
reductions in total [Aβ] and Aβ40 combined with increased Aβ42 and the Aβ42/Aβ40 ratio [46]. 
Those that cannot be grouped due to a lack of data are in group x. Triosomy of chromosome 21 in DS 
and APP duplication and mutations in promoter regions that lead to increased levels of APP may 
show different changes in levels of Aβ species to other mutations and SAD [122, 123]. These genetic 
alterations may form a fourth group that represents an additional pathogenic pathway [122]. 
 
Genetic and molecular data suggest that there are at least three possible pathways to dysfunction 
and that these can be further modulated by features such as propensity of peptides to aggregate as 
oligomers and fibrils due to changes in electrostatic or hydrophobic natures of the substituted amino 
acids. Different molecular pathways associated with FAD have been proposed previously [124, 125] 
in relation to the phenotypic and neuropathological heterogeneity associated with APP mutations 
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[126] and PSENs mutations [53, 127]. In addition, APP duplication and triosomy of chromosome 21 
appear to increase total tau and tau phosphorylation in a manner independent from Aβ while PSENs 
mutations may not [82]. This interpretation of the evidence contrasts with that of the ACH, which 
assumes that all forms of AD, inherited and sporadic, should share the same Aβ-related disease 
pathway. 
 
Increases in Aβ42 seen in FAD with PSENs mutations and the APP mutations p.KM670/671NL and 
p.V717I have been found to precede dementia [103, 128], supporting the ACH where increasing Aβ, 
perhaps specifically Aβ42, is thought to cause AD. However, Scheuner et al also found that the 
average levels of Aβ42 in 71 individuals with SAD (29+/- 2pmol) were not significantly different to 
that measured in 75 controls (27 +/-3pmol) [103]. In this study, only 13% of those with SAD and 3% 
younger controls had elevated Aβ 1-42(3) levels similar to those found in individuals with FAD. This 
suggests that a minority of SAD may have similarities to PSENs associated FAD, supporting the 
multiple pathways perspective of the AMA and PSH. How imbalance between the all various 
peptides, including the shorter Aβ peptides [105, 111, 114, 128] contribute to AD disease processes 
is not clear. According to the ACH, mutations around the γ-cleavage site are associated with 
increased Aβ42 therefore removal of Aβ42 is a rational therapeutic approach. In contrast, both the 
PSH and AMA predict that APP and PSENs mutations associated with reductions in total Aβ may 
represent disease pathways associated with the loss of Aβ physiological functions [46, 48, 129] and 
removal of Aβ per se is unlikely to be beneficial; up-regulation of γ-cleavage or addition of 
physiologically relevant Aβ could be useful in humans.  
 
It is interesting that the group 1 disease associated mutations involve the heparin binding domain, 
(Figure 2), and mutations N-terminal to this, such as APP p.T663M, are neutral. The AMA predicts 
that the group 1 mutations potentially also affect interactions of full length APP, sAPPα and sAPPβ, 
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with consequences for disease progression in addition to any affects due to changes in cleavages or 
behaviour of Aβ. This cannot be assessed with current evidence.   
 
Is Aβ the only defining characteristic of the APP proteolytic system in AD? 
 
The focus on Aβ proposed by the ACH in effect reduces description of the complexity of APP 
proteolytic system to Aβ levels. While APP mutations such as those in group 1 associated with the α-
cleavage site lead to increased Aβ production, often with no change to the Aβ42/Aβ40 ratio, where 
measured, they also lead to a reduction in sAPPα [109, 114, 116]. Those mutations in group 3 
showing reduced expression of total [Aβ] and Aβ40, where measured, lead to an increase in sAPPα 
[116].  Those studies that measure additional fragments [105, 114] independently suggest that it is 
not possible to assign absolute causality to any one fragment with certainty given the changes in 
expression or function of full length APP and other fragments.  
 
Functions associated with sAPPα include promotion of long term potentiation (LTP) [130-132], 
neurite outgrowth [133] and various roles in neuroprotection [134-136]. Significant correlation 
between low levels of sAPPα and poor cognitive function was found in cases with the APP 
p.KM670/671NL double Swedish mutation while no association was found between the levels of Aβ 
and cognition [137] and low levels of sAPPα but not sAPPβ in cerebrospinal fluid (CSF) are associated 
with SAD [138]. The sAPPβ /sAPPα ratio has been found to be higher in those with amyloid 
neuropathological deposits than those without [139]. Both sAPPα and Aβ have important roles in 
regulating synaptic plasticity via LTP [130, 131] and long term depression (LTD) [140-142] 
respectively. Synaptic plasticity may be understood as a dynamic and coherent balance between 
both LTP and LTD and the AMA predicts that this will be associated with the ratios of sAPPα/sAPPβ 
coupled with P3/Aβ, (Figure 1c); neither LTP nor LTD alone can typify neurotoxicity or 
neuroprotection. In a recent study using animal models, immunotherapy targeting Aβ using two 
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different antibodies resulted in increased cortical hyperactivity and this was proposed to underlie 
the lack of cognitive improvement seen in human trials [143]. This hyperactivity is consistent with 
the AMA and PSH, where loss of physiologically relevant Aβ would be expected to reduce LTD and 
lead to increased hyperactivity via the actions of sAPPα and follow on failure of coherent synaptic 
plasticity but unexpected according to the ACH, where removal of Aβ would be expected to alleviate 
neurotoxicity. Taken together, the above evidence suggests that the role of sAPPα in disease 
progression may be more important than the ACH allows and experimental design should be refined 
to include sAPPα, sAPPβ and P3 when Aβ is reported with respect to synaptic plasticity.  
 
How do different hypotheses relate to disease heterogeneity? 
 
The mutations in APP and PSENs genes are only now being comprehensively described and 
summaries are available via the AD and FTD mutation database curated by Cruts et al [144] and the 
Alzforum database [145]. Rare mutations and those recently found e.g. APP p.D678H [146], APP 
p.K687N [109] and APP p.T719P [128], are not adequately described as too few individuals have 
come to autopsy.  
 
Mutations affecting APP at codon 693, Group 2 in Table 1 and Figure 1, have diverse molecular and 
neuropathological effects. In APP Δ693, the charged acidic amino acid glutamic acid is deleted. This 
mutation is uniquely associated intraneuronal oligomerization with no fibrillization and with very 
low levels of amyloid [100, 147]. Both APP p.E693K, where glutamic acid is substituted by the larger 
charged basic side chain of lysine [148] and APP p.E693Q, where glutamic acid is replaced by the 
similarly sized, non- charged negatively polar side chain glutamine [107, 149-154], are associated 
with strokes, CAA and cognitive decline with no tau-related neurofibrillary changes. The APP 
p.E693G mutation, where glutamic acid is replaced by the small non-polar glycine, is associated with 
CAA, abundant plaques and typical tau related neurofibrillary pathology [102, 153-157]. The APP 
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p.E693K, APP p.E693Q and APP p.E693G mutations are also associated with increased deposition of 
Aβ38 not seen in DS, PSEN1 mutations or sporadic disease [158] while APP p.E693G and APP 
p.E693Q are associated with reduced degradation by the insulin degrading enzyme [154]. It is not 
clear whether overall change in sequence (APP ΔE693), size (APP p.E693K and APP p.E693G), charge 
(all APP at codon 693 substitutions) or partial contributions from all these changes are responsible 
for the dramatic differences seen in aggregation, disease association and neuropathology for this 
codon.  
The mutation APP p.A673V, as well as being associated with disease only in the homozygous state, is 
distinguished from all other APP mutations due to large plaque size and vessel associations [126] 
however it shares increased deposition of Aβ38 with APP  mutations at codon 693 [158].  These 
mutations, associated with several different pathological presentations, perhaps represent different 
pathways that could be relevant to deposition of Aβ in various forms and tau-related neurofibrillary 
change. While group 2 may be generally defined by reduced levels of Aβ, individual mutations show 
unique neuropathological features that may derive from additional properties of any amino acid 
substitution. In this respect, each the effects of each mutation should be investigated not only with 
reference to levels of Aβ and other fragments but also the changed molecular properties arising 
from each mutation. It will be interesting to see if the APP p.L705V Italian mutation with CAA, 
increased deposition of Aβ38 [158] and few plaques is associated with reduced Aβ40, Aβ42 and 
Aβ42/Aβ40 in common with group 2 and how the change in charge from basic lysine to non-polar 
valine affects peptide interactions. 
The genetic evidence is consistent with interpretations that these mutations lead to CAA affecting 
vessel walls and deposition of Aβ in brain parenchyma via different but not mutually exclusive 
disease pathways [148, 159, 160] and this may be usefully investigated in relation to 
neuropathologically defined CAA types [161, 162]. CAA may be a distinct pathological process from 
plaque formation, supported by evidence that Aβ(1-42) fragments are associated with diffuse 
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parenchymal deposits whereas Aβ(1-40) is associated with CAA vascular deposition [148]. Mutations 
resulting in changes to size and electrostatic charge may be associated with presence of CAA [163] 
that is independent from any interstitial fluid drainage effects [164, 165].  
 
Mutations associated with FAD collectively offer an opportunity to describe in molecular detail a 
natural history of over and under expression for Aβ and other APP proteolytic fragments and also 
the associations with neuropathology and clinical features for each mutation. Following these 
individuals longitudinally will build a detailed understanding the different relationships between the 
APP proteolytic system, deposition of Aβ as plaques and CAA and how this proteolytic system relates 
to neurofibrillary change. A similar approach in populations to fully describe molecular and 
neuropathological change in ageing and disease will allow the identification of which pathways these 
mutations promote are most relevant to SAD. 
 
All the hypotheses considered here, the AMA, the PSH and the ACH, allow changes in Aβ, whether 
due in concentration or structural features associated with substitution of amino acids, to modulate 
disease pathways. However, the ACH does not adequately explain the group 2 mutations, (Table 1, 
Figure 2), where levels of Aβ fragments are reduced. For APP mutations at codon 693, reduced Aβ is 
associated with disease, whereas for APP p.A673T reduced Aβ is not. A combination of the AMA and 
PSH for interpretation relating to APP mutations may be a better guide for experimental design.  
 
From the perspective of the AMA and PSH, heterogeneity in clinical and neuropathological 
presentations in FAD and SAD suggests multiple pathways at the molecular level, where therapeutic 
strategies would be targeted. In contrast, the ACH suggests that all pathways are unified by Aβ and 
removal of Aβ is the best strategy. However, it is not clear whether what we currently understand as 
AD represents one or many disease subtypes or how SAD relates to FAD. A more detailed 
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characterisation of the range of amyloid and neurofibrillary deposits, both in terms of molecular 
composition and morphological appearance in the human population is urgently required. 
 
Translating pre-clinical AD research to therapeutics 
 
The translation of pre-clinical research to the human population presents significant challenges. 
Failure to replicate pre-clinical science has become a recent focus [166, 167] with various factors 
highlighted such as excess significance in animal research [168], poor use of statistics [169] and 
problems of inter-species generalizability [170, 171]. If we further consider the potential 
confounding due to anti Aβ antibody cross reactivities [87], we are uncertain as to what are relevant 
or irrelevant results that should be taken forward as therapeutic targets in AD.  
 
While FAD can be readily identified and separated into subtypes by genetic characterisation, the lack 
of qualitative clinical markers in SAD is a significant impediment to the design of randomised 
controlled trials as there is no way to assign cases and controls with certainty. All AD clinical 
biomarkers lie on continua where thresholds are defined that best separate those with from those 
without dementia, however, no pre-defined threshold has been applied systematically between 
studies [16, 18, 172]. The relationship between biomarkers such as CSF or plasma levels of protein 
fragments, MRI markers of amyloid build up or atrophy and disease progression is not clear and 
different markers can lead to conflicting results [6, 7]. No biomarkers of AD have been systematically 
studied in population cohorts where most dementia syndrome occurs and where validity is best 
tested. Additionally, the relationship between neuropathology and disease progression is not yet 
fully understood so that it is not clear what the biomarkers or the neuropathology represent in 
relation to cognitive change. The lack of validated biomarkers underlies the difficulties involved in 
following human cohorts over time and is a serious limitation in the search for therapeutic 
treatments. 
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Within population studies, neuropathological (blind to clinical information) and clinical diagnoses of 
AD are not well matched and most report cases with dementia and no AD-related neuropathology 
and cases with significant neuropathological load and no dementia [11]. Case control studies often 
select cases and controls by combining clinical and neuropathological information with the effect of 
eliminating these two categories from the study, leading to selection bias and an over-estimate of 
associations. Population studies avoid this selection bias but because they do not separate out 
different disease types, this approach leads to under-estimates of associations. Both approaches 
reveal valuable information and should be used in combination. A population approach would be 
very useful in describing the clinical, neuropathological and molecular heterogeneity associated with 
different FAD mutations. This would give a better description of each and find specific differences 
and commonalities that would tease apart the possible disease pathways and allow the selection of 
cases and controls in randomised controlled trials with greater confidence.  
 
Conclusions 
 
Simplicity is one advantage of the ACH; it is easy to describe Aβ as neurotoxic and causal in AD. 
However, this simplicity is also its great weakness in that it does not allow the many roles and 
changing behaviours of Aβ to be placed in the wider context of the APP proteolytic system as a 
whole. Experimental design based on the ACH is focussed on Aβ and lacks the systematic approach 
demanded by the AMA that requires all fragments to be assessed in any investigation. The use of 
Occam’s razor focuses attention solely on Aβ and in effect removes considerations of the complexity 
of APP physiology and biochemistry from experimental design, creating unnecessary division 
between the complexity of the APP proteolytic system and Aβ, one of its components. This has led 
to missing information and a poor understanding of the APP proteolytic system as a whole. We do 
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not yet have the evidence to say with certainty which model of disease progression is more 
representative of actual disease pathways in humans.  
 
There are some research questions that the AMA will allow that the ACH does not, especially with 
respect to the loss of Aβ function and the dynamic balance between all the proteolytic fragments. 
Since the AMA includes other cellular systems as drivers in the regulation and control of APP 
proteolytic processing, the AMA throws a spotlight on other hypotheses ranging from those based 
on factors relating to wider cellular systems such as synaptic plasticity, cholesterol homeostasis, cell 
cycle, metabolism and oxidative stress, other cell signalling cascades, and ageing in a non-
hierarchical manner. This may better represent multifactorial disease pathways recognised in SAD. 
An integrative approach should lead to a much better understanding of the relationships between all 
areas involved in AD research.  We do not yet have the detailed evidence required to understand the 
role of the APP proteolytic system either in normal or disease states. We need refined theoretical 
disease models to generate better experimental designs both clinically and pre-clinically, in order to 
generate this evidence.  
 
Supplementary information is available at Molecular Psychiatry’s website
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Figure 1 Hypotheses of disease pathways in AD relevant to the interpretation of APP mutations 
 
1a: Adapted from [44]; 1b: adapted from [46, 60]; 1c: Green α-cleavage; Red β-cleavage; Purple β’-
cleavage; Blue γ-cleavage; Grey caspase cleavage. Thickness of arrows represents average 
percentage flow through the pathways as determined by ratios of P3:Aβ’:Aβ as described in [111]. 
Functional block A arises due to the synergistic interactions of full length APP, sAPPα, sAPPβ and 
sAPPβ’ and may involve examples of agonism and antagonism. Functional block B arises due to the 
synergistic interactions of the various fragment lengths following γ-cleavage with N- and C- terminal 
variations and may involve examples of agonism and antagonism. Other functions are associated 
with the AICDs following γ- and caspase cleavages and general catabolism of all fragments not 
represented here. 
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Figure 2 Disease associated APP Mutations by location  
Adapted from [86] and [144]. Groups are defined by the qualitative changes in Aβ levels as described 
in Table 1. 
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Table 1 Groupings of pathogenic APP mutations according to qualitative changes of Aβ fragments. 
Mutation 
position 
Group Disease association/neuropathology Fragments refs 
KM670/ 
671NL 
Swedish 
1 AD; numerous plaques and NFT, variable CAA; 
increases in expression of longer forms of APP but 
not APP695 
↑[Aβ]  
↑Aβ40  
↑ Aβ42  
 = / ↓ 
Aβ42/Aβ40  
[103, 
173, 
174] 
A673T 2 Protective mutation, reduced Aβ, Aβ40 and Aβ42, 
increased sAPPα 
↓[Aβ] 
↓ Aβ40 
↓ Aβ42 
[101, 
106] 
A673V 1 AD only when homozygous; extensive Aβ deposition, 
CAA, increased Aβ40 (not Aβ42) fibrillization; 
amyloid plaques include both Aβ40 and Aβ42; few 
diffuse  deposits; can be distinguished from other 
FAD or SAD by large plaque size and vessel 
associations  
↑[Aβ]  
↑Aβ40  
↑Aβ42  
 = Aβ42/Aβ40 
↑ Aβ 11-X  
[106, 
114, 
126] 
H677R 
English 
x  =[Aβ]  
= Aβ42 
[175]
D678H 
Taiwan 
1 AD with CAA and micro-haemorrhages; changes in 
Aβ are extracellular; no change in intracellular levels; 
increased C99/C83 ratio; no change in BACE2 C89 
product; mutation alters APP sorting 
↑[Aβ]  
↑Aβ40  
↑ Aβ42  
↑Aβ42/Aβ40 
[117, 
146, 
175] 
D678N  
Tottori 
x AD =[Aβ]  
= Aβ42  
[175, 
176] 
E682K 
Leuven 
1 AD ↑[Aβ]  
↑Aβ40  
↑ Aβ42  
↑Aβ42/Aβ40 
↓ Aβ 11-X  
[105]
K687N 
 
1 AD ↑[Aβ]  
↑Aβ40  
↑ Aβ42  
[109]
A692G 
Flemish 
1 CAA, AD or both; large cored amyloid plaques 
centred on vessels; in contrast to other AD cored 
plaques are mostly Aβ40, diffuse Aβ42 deposits; 
severe neurofibrillary pathology 
↑[Aβ]  
↑Aβ40  
↑ Aβ42  
↑Aβ42/Aβ40 
[102, 
105, 
107, 
111, 
153, 
177-
179] 
ΔE693  
Osaka 
2 AD; very low levels of amyloid on PiB MRI; 
oligomerization with no fibrillization; uniquely 
increased intraneuronal Aβ oligomers 
↓[Aβ] 
↓ Aβ40 
↓ Aβ42 
↓ / 
=Aβ42/Aβ40 
[100, 
147] 
E693K  
Italian 
2 CAA, strokes and cognitive decline; no neurofibrillary 
changes; capillary CAA associated with Aβ42, vessels 
associated mostly with Aβ40; Aβ42 in diffuse 
deposits 
↓ / =Aβ40 
↓ Aβ42 
↓ Aβ42/Aβ40 
[148] 
E693Q  
Dutch 
2 CAA and cognitive decline; no neurofibrillary 
changes; mostly Aβ40 in vessels and Aβ42 in diffuse 
deposits; reduced Aβ proteolysis by IDE 
↓ / =Aβ40 
↓ Aβ42 
↓ Aβ42/Aβ40 
[107, 
149-
154] 
E693G  
Arctic 
2 CAA and AD, typical AD neurofibrillary pathology, 
abundant amyloid plaques reactive with both Aβ40 
and Aβ42; many plaques ring-like and lacking cores; 
accelerated formation of oligomers and protofibrils 
by Aβ40; reduced Aβ proteolysis by IDE 
↓ / =Aβ40 
↓ Aβ42 
↓ Aβ42/Aβ40 
[102, 
153-
157] 
D694N  
Iowa 
x CAA and AD; widespread NFT; increased  Aβ40 in 
amyloid plaques 
[180]
L705V  
Italian 
x CAA and cognitive decline; no amyloid plaques or 
NFT; vessels show both Aβ40 and Aβ42 
 [181] 
G709S 
 
x AD; shifts Aβ profile from Aβ40 to Aβ39 Aβ37 ↓ Aβ40 
↑ Aβ38 & Aβ39 
[182]
A713T 
 
x CAA, stroke and AD; pathogenic in both 
heterozygous and homozygous states; later age of 
onset in heterozygotes 
= Aβ42/Aβ40 [183-
186] 
T714A  
Iranian 
x AD; variable age at on-set; epilepsy ↓ Aβ42 [187, 
188] 
T714I 
Austrian 
3 AD; variable CAA; epilepsy ↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
[94, 
118, 
189] 
V715M 
French 
3 AD ↓ [Aβ] 
↓ Aβ40 
= Aβ42 
↑ Aβ42/Aβ40 
[116, 
118, 
190, 
191] 
V715A 
German 
3 AD ↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
[118, 
192, 
193] 
I716V  
Florida 
3 AD  = or↑ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
↑ Aβ38 
[104, 
113, 
118] 
I716F 
 
3 AD with CAA; extensive neurofibrillary pathology; 
oligomeric N-truncated pyroglutamate Aβ deposition 
associated with clinical symptoms; Lewy bodies also 
present and associated with movement disorder 
↓ [Aβ] 
↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
↑ Aβ38 
[113, 
119, 
194, 
195] 
I716T 
 
x AD ↑ Aβ42/Aβ40 
↑ Aβ38 
[113, 
196] 
V717I  
London 
3 AD; numerous amyloid plaques and NFT, variable 
CAA 
↓ [Aβ] 
↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
↑ Aβ38 
[103, 
104, 
107, 
108, 
118, 
119, 
197] 
V717L  
Indiana 
3 AD ↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
[118]
V717F  
Indiana 
3 AD ↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
[102]
V717G 
 
3 AD; progressive amnesia ↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
[198, 
199] 
T719P 
 
x AD [128]
L723P 
Australia
n 
x AD ↑ Aβ42 
↑ Aβ42/Aβ40 
[121, 
200] 
K724N 
Belgian 
3 AD ↓ Aβ40 
↑ Aβ42 
↑ Aβ42/Aβ40 
↑ Aβ38 & Aβ39 
[201] 
APP 
duplicati
on 
x Duplication size varies  and may include additional 
genes; duplications may not always be fully 
penetrant; those leading to increased APP levels 
share some features with DS  
 [202-
206] 
APP 
promoter 
x Promoter mutations leading to increased APP levels 
share some features with DS; may vary between 
specific mutations 
 [207, 
208] 
DS x Increased Aβ oligomers; complex changes in levels of 
Aβ species in plasma and CSF; levels of Aβ40 while 
initially higher in DS than normal controls are 
reduced with DS dementia; levels of Aβ42 and 
Aβ42/Aβ40 are initially lower but increase with DS 
dementia 
[122, 
123, 
209-
211] 
-detailed descriptions are not available for recently discovered mutations as individuals have not yet 
come to autopsy. Further detail is available in Supplementary Table 1. 
